background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

PROTEIN/PEPTIBODY

Proteins, large molecules comprised of long chains of amino acids folded into three-dimensional shapes, are responsible for nearly every function of the human body.1 Therapeutic proteins can be used to replace or augment a protein that is abnormal or deficient in a particular disease.2,3

Peptides are small proteins comprised of short chains of amino acids. While peptides have functions and attributes that give them significant therapeutic potential, they also tend to be rapidly cleared from the body.4,5 By fusing a peptide to part or all of an antibody, a peptibody combines the biological activity of a peptide with the longer duration of activity of an antibody—which may broaden its therapeutic utility.5

CIT, chemotherapy-induced thrombocytopenia; GvHD, graft versus host disease; IL-2Rα, interleukin 2 receptor alpha; TPO-R, thrombopoietin receptor.

References
1. National Institutes of Health. https://ghr.nlm.nih.gov/primer/howgeneswork/protein. Accessed 9/10/20. 2. Dimitrov DS. Methods Mol Biol. 2012;899:1-26. 3. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 4. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/peptide. Accessed 9/10/20. 5. Shimamoto G, et al. MAbs. 2012;4:586-591. 6. Pol JG, et al. J Exp Med. 2020;217:pii: e20191247. doi:10.1084/jem.20191247. 7. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03422627. Accessed 9/10/20. 8. Yang AS. Semin Hematol. 2015;52:12-15. 9. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03937154. Accessed 9/10/20.
Molecule
Modality3
Target3,6
Areas of Investigation7
Efavaleukin alfa (AMG 592)
Modality3
PROTEIN/PEPTIBODY
Target3,6
Areas of Investigation7
Molecule
Modality3,8
Target3
Areas of Investigation3,9
Romiplostim
Modality3,8
PROTEIN/PEPTIBODY
Target3
Areas of Investigation3,9

CIT, chemotherapy-induced thrombocytopenia; GvHD, graft versus host disease; IL-2Rα, interleukin 2 receptor alpha; TPO-R, thrombopoietin receptor.

References
1. National Institutes of Health. https://ghr.nlm.nih.gov/primer/howgeneswork/protein. Accessed 9/10/20. 2. Dimitrov DS. Methods Mol Biol. 2012;899:1-26. 3. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 4. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/peptide. Accessed 9/10/20. 5. Shimamoto G, et al. MAbs. 2012;4:586-591. 6. Pol JG, et al. J Exp Med. 2020;217:pii: e20191247. doi:10.1084/jem.20191247. 7. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03422627. Accessed 9/10/20. 8. Yang AS. Semin Hematol. 2015;52:12-15. 9. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03937154. Accessed 9/10/20.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.